Transcriptional Profiling of Polycythemia Vera Identifies Gene Expression Patterns Both Dependent and Independent from the Action of JAK2V617F

被引:30
作者
Berkofsky-Fessler, Windy [3 ]
Buzzai, Monica
Kim, Marianne K-H.
Fruchtman, Steven [4 ]
Najfeld, Vesna [5 ]
Min, Dong-Joon
Costa, Fabricio F. [2 ]
Bischof, Jared M. [2 ]
Soares, Marcelo B. [2 ]
McConnell, Melanie Jane [9 ]
Zhang, Weijia [6 ]
Levine, Ross [7 ,8 ]
Gilliland, D. Gary [10 ]
Calogero, Raffaele [11 ]
Licht, Jonathan D. [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Childrens Mem Res Ctr, Canc Biol & Epigenom Program, Chicago, IL 60611 USA
[3] Hoffmann La Roche Inc, Pharma Res & Early Dev, Translat Res Sci, Nutley, NJ 07110 USA
[4] Allos Therapeut, Princeton, NJ USA
[5] Mt Sinai Sch Med, Tisch Canc Inst, Dept Pathol, New York, NY USA
[6] Mt Sinai Sch Med, Dept Med, New York, NY USA
[7] Mem Sloan Kettering Canc Ctr, Dept Med, Human Oncol & Pathogenesis Program, New York, NY 10021 USA
[8] Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY 10021 USA
[9] Malaghan Inst Med Res, Wellington, New Zealand
[10] Merck Res Labs, West Point, PA USA
[11] Univ Toronto, S Luigi Hosp, Dept Sci Clin & Biol, Toronto, ON M5S 1A1, Canada
关键词
ACQUIRED UNIPARENTAL DISOMY; TUMOR-SUPPRESSOR GENE; V617F MUTATION; MYELOPROLIFERATIVE DISORDERS; JAK2; INHIBITOR; TET2; MUTATIONS; CELL-LINE; MYELOFIBROSIS; JAK2-V617F; REGULATOR;
D O I
10.1158/1078-0432.CCR-10-1092
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To understand the changes in gene expression in polycythemia vera (PV) progenitor cells and their relationship to JAK2V617F. Experimental Design: Messenger RNA isolated from CD34(+) cells from nine PV patients and normal controls was profiled using Affymetrix arrays. Gene expression change mediated by JAK2V617F was determined by profiling CD34+ cells transduced with the kinase and by analysis of leukemia cell lines har-boring JAK2V617F, treated with an inhibitor. Results: A PV expression signature was enriched for genes involved in hematopoietic development, inflammatory responses, and cell proliferation. By quantitative reverse transcription-PCR, 23 genes were consistently deregulated in all patient samples. Several of these genes such as WT1 and KLF4 were regulated by JAK2, whereas others such as NFIB and EVI1 seemed to be deregulated in PV by a JAK2-independent mechanism. Using cell line models and comparing gene expression profiles of cell lines and PV CD34+ PV specimens, we have identified panels of 14 JAK2-dependent genes and 12 JAK2-independent genes. These two 14- and 12-gene sets could separate not only PV from normal CD34+ specimens, but also other MPN such as essential thrombocytosis and primary myelofibrosis from their normal counterparts. Conclusions: A subset of the aberrant gene expression in PV progenitor cells can be attributed to the action of the mutant kinase, but there remain a significant number of genes characteristic of the disease but deregulated by as yet unknown mechanisms. Genes deregulated in PV as a result of the action of JAK2V617F or independent of the kinase may represent other targets for therapy. Clin Cancer Res; 16(17); 4339-52. (C) 2010 AACR.
引用
收藏
页码:4339 / 4352
页数:14
相关论文
共 62 条
  • [11] Fiedler W, 2000, CANCER-AM CANCER SOC, V88, P344, DOI 10.1002/(SICI)1097-0142(20000115)88:2<344::AID-CNCR14>3.0.CO
  • [12] 2-6
  • [13] FRIDMAN J, 2007, ASH ANN M, V110, P3538
  • [14] Bioconductor: open software development for computational biology and bioinformatics
    Gentleman, RC
    Carey, VJ
    Bates, DM
    Bolstad, B
    Dettling, M
    Dudoit, S
    Ellis, B
    Gautier, L
    Ge, YC
    Gentry, J
    Hornik, K
    Hothorn, T
    Huber, W
    Iacus, S
    Irizarry, R
    Leisch, F
    Li, C
    Maechler, M
    Rossini, AJ
    Sawitzki, G
    Smith, C
    Smyth, G
    Tierney, L
    Yang, JYH
    Zhang, JH
    [J]. GENOME BIOLOGY, 2004, 5 (10)
  • [15] Platelets express steroidogenic 17β-hydroxysteroid dehydrogenases -: Distinct profiles predict the essential thrombocythemic phenotype
    Gnatenko, DV
    Cupit, LD
    Huang, EC
    Dhundale, A
    Perrotta, PL
    Bahou, WF
    [J]. THROMBOSIS AND HAEMOSTASIS, 2005, 94 (02) : 412 - 421
  • [16] Goerttler PS, 2005, BRIT J HAEMATOL, V129, P138, DOI 10.1111/j.1365-2141.2005.05416.x
  • [17] Frequent CBL mutations associated with 11q acquired uniparental disomy in myeloproliferative neoplasms
    Grand, Francis H.
    Hidalgo-Curtis, Claire E.
    Ernst, Thomas
    Zoi, Katerina
    Zoi, Christine
    McGuire, Carolann
    Kreil, Sebastian
    Jones, Amy
    Score, Joannah
    Metzgeroth, Georgia
    Oscier, David
    Hall, Andrew
    Brandts, Christian
    Serve, Hubert
    Reiter, Andreas
    Chase, Andrew J.
    Cross, Nicholas C. P.
    [J]. BLOOD, 2009, 113 (24) : 6182 - 6192
  • [18] Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1)
    Guglielmelli, Paola
    Zini, Roberta
    Bogani, Costanza
    Salati, Simona
    Pancrazzi, Alessandro
    Bianchi, Elisa
    Mannelli, Francesco
    Ferrari, Sergio
    Le Bousse-Kerdiles, Marie-Caroline
    Bosi, Alberto
    Barosi, Giovanni
    Migliaccio, Anna Rita
    Manfredini, Rossella
    Vannucchi, Alessandro M.
    [J]. STEM CELLS, 2007, 25 (01) : 165 - 173
  • [19] Abnormal production of interleukin (IL)-11 and IL-8 in polycythaemia vera
    Hermouet, S
    Godard, A
    Pineau, D
    Corre, I
    Raher, S
    Lippert, E
    Jacques, Y
    [J]. CYTOKINE, 2002, 20 (04) : 178 - 183
  • [20] Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders
    Hexner, Elizabeth O.
    Serdikoff, Cynthia
    Jan, Mahfuza
    Swider, Cezary R.
    Robinson, Candy
    Yang, Shi
    Angeles, Thelma
    Emerson, Stephen G.
    Carroll, Martin
    Ruggeri, Bruce
    Dobrzanski, Pawel
    [J]. BLOOD, 2008, 111 (12) : 5663 - 5671